Effect of Cholecalciferol as Adjunctive Therapy With Insulin on Protective Immunologic Profile and Decline of Residual beta-Cell Function in New-Onset Type 1 Diabetes Mellitus


Autoria(s): Gabbay, Mônica A. L.; Sato, Maria Notomi; Finazzo, Claudia; Duarte, Alberto Jose da Silva; Dib, Sergio A.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

07/11/2013

07/11/2013

2012

Resumo

Objective: To evaluate the effect of vitamin D-3 on cytokine levels, regulatory T cells, and residual beta-cell function decline when cholecalciferol (vitamin D-3 administered therapeutically) is given as adjunctive therapy with insulin in new-onset type 1 diabetes mellitus (T1DM). Design and Setting: An 18-month (March 10, 2006, to October 28, 2010) randomized, double-blind, placebo-controlled trial was conducted at the Diabetes Center of Sao Paulo Federal University, Sao Paulo, Brazil. Participants: Thirty-eight patients with new-onset T1DM with fasting serum C-peptide levels greater than or equal to 0.6 ng/mL were randomly assigned to receive daily oral therapy of cholecalciferol, 2000 IU, or placebo. Main Outcome Measure: Levels of proinflammatory and anti-inflammatory cytokines, chemokines, regulatory T cells, hemoglobin A(1c), and C-peptide; body mass index; and insulin daily dose. Results: Mean (SD) chemokine ligand 2 (monocyte chemoattractant protein 1) levels were significantly higher (184.6 [101.1] vs 121.4 [55.8] pg/mL) at 12 months, as well as the increase in regulatory T-cell percentage (4.55%[1.5%] vs 3.34%[1.8%]) with cholecalciferol vs placebo. The cumulative incidence of progression to undetectable (<= 0.1 ng/mL) fasting C-peptide reached 18.7% in the cholecalciferol group and 62.5% in the placebo group; stimulated C-peptide reached 6.2% in the cholecalciferol group and 37.5% in the placebo group at 18 months. Body mass index, hemoglobin A(1c) level, and insulin requirements were similar between the 2 groups. Conclusions: Cholecalciferol used as adjunctive therapy with insulin is safe and associated with a protective immunologic effect and slow decline of residual beta-cell function in patients with new-onset T1DM. Cholecalciferol may be an interesting adjuvant in T1DM prevention trials.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Coordenadoria de Aperfeicoamento do Pessoal de Ensino SuperiorProgramas de Excelencia, Ministry of Education of Brazil

Coordenadoria de Aperfeicoamento do Pessoal de Ensino Superior-Programas de Excelencia, Ministry of Education of Brazil

Identificador

ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, CHICAGO, v. 166, n. 7, pp. 601-607, JUL, 2012

1072-4710

http://www.producao.usp.br/handle/BDPI/42861

http://archpedi.jamanetwork.com/article.aspx?articleid=1212223

Idioma(s)

eng

Publicador

AMER MEDICAL ASSOC

CHICAGO

Relação

ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

Direitos

closedAccess

Copyright AMER MEDICAL ASSOC

Palavras-Chave #REGULATORY T-CELLS #CYTOKINE-INDUCED APOPTOSIS #VITAMIN-D #PANCREATIC-ISLETS #1-ALPHA,25-DIHYDROXYVITAMIN D-3 #AUTOIMMUNE-DISEASES #EXPRESSION #RECEPTOR #PERSPECTIVES #PATHOGENESIS #PEDIATRICS
Tipo

article

original article

publishedVersion